NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

HER2-positiveAdenocarcinomaBile Duct CancerBiliary Tract CancerBladder CancerBreast CancerBreast NeoplasmCarcinoma, DuctalCarcinoma, HepatocellularCancerLung Cancer, Non-Small-CellCarcinoma, Ovarian EpithelialCarcinoma, Small CellCarcinoma, SquamousCarcinoma, Transitional CellColorectal CancerEsophagogastric Junction NeoplasmsInflammatory Breast CancerStomach NeoplasmsMalignant NeoplasmsOvarian NeoplasmsPancreatic CancerHER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Gastric CancerHER-2 Protein OverexpressionHER-2 Gene AmplificationProstate CancerHead and Neck CancerEndometrial CancerLung Cancer, Small Cell

Interventions

BIOLOGICAL

CT-0508

anti-HER2 CAR macrophages

BIOLOGICAL

Pembrolizumab

anti-PD antibody

Trial Locations (7)

19104

Abramson Cancer Center, Philadelphia

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

37203

Tennessee Oncology / Sarah Cannon Research Institute, Nashville

77030

M D Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

97239

OHSU Knight Cancer Institute, Portland

98109

Fred Hutchinson Cancer Center, Seattle